Luis Caminal‐Montero

Author

Hospital Universitario Central de Asturias ORCID

Also Known As

J J Blanch Sancho, J. Bernardino Díaz-López, José Ignacio Fernández Bernaldo de Quirós, Jürgen Brunner, L C Montero, L Caminal, L Caminal Montero, L Caminal-Montero, L. CAMINAL, L. Caminal

184

Publications

2.1K

Citations

H-Index

Concepts

All Affiliations

Hospital Universitario Central de Asturias Universidad de Oviedo Consorci Institut D'Investigacions Biomediques August Pi I Sunyer Hospital Universitario de La Princesa Instituto de Investigación Sanitaria del Principado de Asturias

About

Luis Caminal‐Montero is an author at Hospital Universitario Central de Asturias specializing in medicine, autoimmune disease, and autoimmunity.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	9	9	305
2	Public Health	2	2	55
3	Allergy	1	1	13
4	Clinical Immunology	1	1	13
5	Emergency Medicine	1	1	39

Luis Caminal‐Montero

Publications

1.6K

Citations

H-Index

Page 1

	Year	Citations
A Large-Scale Genetic Analysis Reveals a Strong Contribution of the HLA Class II Region to Giant Cell Arteritis Susceptibility F. David Carmona, Sarah Mackie, Jose‐Ezequiel Martín, The American Journal of Human Genetics	2015	174
Clinical characteristics and outcome of Spanish patients with ANCA-associated vasculitides Roser Soláns-Laqué, G. Fraile, Mónica Rodríguez‐Carballeira, Medicine	2017	151
Off-label use of rituximab in 196 patients with severe, refractory systemic autoimmune diseases. Manuel Ramos‐Casals, Francisco José García Hernández, E de Ramón, PubMed	2010	140
A Genome-wide Association Study Identifies Risk Alleles in Plasminogen and P4HA2 Associated with Giant Cell Arteritis F. David Carmona, Augusto Vaglio, Sarah Mackie, The American Journal of Human Genetics InflammationGenome-wide Association StudyVascular DiseaseVasculitisDisease Mechanism	2016	101
Registry of the Spanish Network for Systemic Sclerosis Carmen Pilar Simeón‐Aznar, Vicent Fonollosa‐Pla, Carles Tolosa-Vilella, Medicine	2015	87
A pathogenic IFNα, BLyS and IL-17 axis in Systemic Lupus Erythematosus patients Patricia López, Javier Rodríguez‐Carrio, Luis Caminal‐Montero, Scientific Reports	2016	83
Clinical associations of anti-SSA/Ro60 and anti-Ro52/TRIM21 antibodies: Diagnostic utility of their separate detection Aurora Menéndez, Jesús María Fernández Gómez, Esther Escanlar, Autoimmunity	2012	75
Rates of, and risk factors for, severe infections in patients with systemic autoimmune diseases receiving biological agents off-label Cándido Díaz‐Lagares, R. Pérez-Álvarez, Francisco José García Hernández, Arthritis Research & Therapy	2011	70
Off-label use of rituximab for systemic lupus erythematosus in Europe Monica Rydén‐Aulin, Dimitrios T. Boumpas, Irene E. M. Bultink, Lupus Science & Medicine	2016	65
Spanish cohort of VEXAS syndrome: clinical manifestations, outcome of treatments and novel evidences about UBA1 mosaicism José M. Mascaró, Ignasi Rodríguez‐Pintó, Gabriela Poza, Annals of the Rheumatic Diseases	2023	63

Page 1